ProNoxis AB
556773-2341ActiveDeveloping small molecule drugs targeting NOX2 activation for inflammation treatment.
Biotechnology R&D Companypronoxis.com
Yleiskatsaus
- 0
- Työntekijät
- 150–199t SEK
- Liikevaihto
- 2008
- Perustettu
Avainpäättäjät
Peter Olofsson
CEO
@pronoxis.com+46709XXXXXX
Kuvaus
ProNoxis is a specialized biotechnology company focused on the preclinical exploration of novel small-molecule therapeutics. Its core mission is developing oral drugs to treat chronic inflammatory, autoimmune, and infectious diseases. The company targets a unique mechanism by developing agonists tha...